EXTON, Pa., Feb. 5 ViroPharma Incorporated(Nasdaq: VPHM) today announced that Vincent Milano, chief financial officerand chief operating officer of ViroPharma, will present at the BIO CEO &Investor Conference at 12:30 P.M. ET on Monday, February 11, 2008. Theconference is being held at the Waldorf=Astoria, in New York.
ViroPharma's presentation will be webcast live for investors throughwww.viropharma.com and available through February 28, 2008.
About ViroPharma Incorporated
ViroPharma Incorporated is a biopharmaceutical company dedicated to thedevelopment and commercialization of products that address serious diseasestreated by physician specialists and in hospital settings. ViroPharmacommercializes Vancocin(R), approved for oral administration for treatment ofantibiotic-associated pseudomembranous colitis caused by Clostridium difficileand enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the packageinsert at http://www.viropharma.com/docs/Vancocin_pi_2007.htm). ViroPharmacurrently focuses its drug development activities in viral diseases includingcytomegalovirus (CMV) and hepatitis C (HCV). For more information onViroPharma, visit the company's website at www.viropharma.com.
SOURCE ViroPharma Incorporated